Total 4-P MACE

There is 1 paper on total 4-P MACE in aging research: 1 trial in people. The newest story, Oct 26, 2026: “Evolocumab reduced total cardiovascular events in high-risk patients”.

Disease

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on total 4-P MACE

  • Human trial1

Interventions

1

Evolocumab

downin humans1

1 study
  1. Evolocumab decreases total 4-P MACE in humans (20% fewer total events (IRR 0.80, 95% CI 0.71-0.90)).

    “and total events by 20% (IRR 0.80, 95% CI 0.71-0.90; p<0.001)”

    Human trial4-P MACE includes ischemia-driven arterial revascularization; first and subsequent events analyzed togethermedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    ESC Congress 2026 abstract

More on Evolocumab

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months
ESC Congress 2026 Abstract

Evolocumab reduced total cardiovascular events in high-risk patients

Evolocumab reduced the combined rate of coronary heart disease deaths, heart attacks and strokes caused by blocked blood flow by 27% versus placebo.Evolocumab reduced the combined rate of coronary heart disease deaths, heart attacks and strokes caused by blocked blood flow by 27% versus placebo.

Randomized trial · 12,257 peopleEvolocumab